Aspira Women's Health (AWH) 10-K 28 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 22, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Registrant Name	VERMILLION, INC.
Entity Central Index Key	0000926617
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Filer Category	Non-accelerated Filer
Trading Symbol	vrml
Entity Public Float			$ 33,929,264
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		75,532,748

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 9,360	$ 5,539
Accounts receivable	786	205
Prepaid expenses and other current assets	550	459
Inventories	92	102
Total current assets	10,788	6,305
Property and equipment, net	608	1,181
Other assets	12	11
Total assets	11,408	7,497
Current liabilities:
Accounts payable	950	745
Accrued liabilities	1,825	1,650
Short-term debt	189	185
Other current liabilities		29
Total current liabilities	2,964	2,609
Long-term debt	1,292	1,481
Total liabilities	4,256	4,090
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at December 31, 2018 and 2017
Common stock, $0.001 par value, 150,000,000 shares authorized; 75,501,394 and 60,036,017 shares issued and outstanding at December 31, 2018 and 2017, respectively	75	60
Additional paid-in capital	414,001	399,400
Accumulated deficit	(406,924)	(396,053)
Total stockholders' equity	7,152	3,407
Total liabilities and stockholders' equity	$ 11,408	$ 7,497

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Consolidated Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	75,501,394	60,036,017
Common stock, shares outstanding	75,501,394	60,036,017

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Revenue:
Revenue		$ 3,053	$ 3,121
Cost of revenue:
Cost of revenue		3,142	2,914
Gross profit /(loss)		(89)	207
Operating expenses:
Research and development	[1]	550	837
Sales and marketing	[1]	5,642	4,268
General and administrative	[1]	5,052	5,543
Total operating expenses		11,244	10,648
Loss from operations		(11,333)	(10,441)
Interest (expense) income , net		(22)	(42)
Other expense)/ income, net		(16)	(14)
Net loss		(11,371)	(10,497)
Deemed dividend on warrant repricing			(942)
Net loss attributable to common stockholders		$ (11,371)	$ (11,439)
Net loss per share attributable to common stockholders - basic and diluted		$ (0.16)	$ (0.20)
Weighted average common shares used to compute basic and diluted net loss per common share		70,085,842	56,943,596
Product [Member]
Revenue:
Revenue		$ 2,772	$ 2,853
Cost of revenue:
Cost of revenue	[1]	2,044	1,756
Service [Member]
Revenue:
Revenue		281	268
Cost of revenue:
Cost of revenue	[1]	$ 1,098	$ 1,158
[1]	Non-cash stock-based compensation expense included in expenses

Consolidated Statements Of Op_2

Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cost Of Revenue [Member]
Stock-based compensation expense	$ 124	$ 136
Research And Development [Member]
Stock-based compensation expense	6	9
Sales And Marketing [Member]
Stock-based compensation expense	102	160
General And Administrative [Member]
Stock-based compensation expense	$ 869	$ 1,134

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance (in shares) at Dec. 31, 2016		52,328,492
Balance at Dec. 31, 2016		$ 52	$ 389,266	$ (385,556)	$ 3,762
Net loss				(10,497)	(10,497)
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs (in shares)		3,747,125
Common stock and warrants issued in conjunction with private placement sale, net of issuance costs		$ 4	5,123		5,127
Common stock issued in conjunction with exercise of warrants, net of issuance costs (in shares)		3,796,818
Common stock issued in conjunction with exercise of warrants, net of issuance costs		$ 4	3,572		3,576
Common stock issued for restricted stock awards (in shares)		163,582
Common stock issued for restricted stock awards			335		335
Stock compensation charge			1,104		1,104
Balance (in shares) at Dec. 31, 2017		60,036,017
Balance at Dec. 31, 2017		$ 60	399,400	(396,053)	3,407
Net loss				(11,371)	(11,371)
ASC 606 Adjustment to retained earnings at Dec. 31, 2017				500	500
Common stock issued in conjunction with public offering, net of issuance costs (in shares)		10,000,000
Common stock issued in conjunction with public offering, net of issuance costs		$ 10	8,980		8,990
Preferred stock issued in conjunction with public offering net of issuance costs (in shares)	50,000
Preferred stock issued in conjunction with public offering net of issuance costs			4,496		$ 4,496
Common stock issued in conjuntion with exercise of stock options (in shares)		32,500			32,500
Common stock issued in conjuntion with exercise of stock options			29		$ 29
Preferred stock converted to common stock (in shares)	(50,000)	5,000,000
Preferred stock converted to common stock		$ 5	(5)
Common stock issued for restricted stock awards (in shares)		432,877
Common stock issued for restricted stock awards			438		438
Stock compensation charge			663		663
Balance (in shares) at Dec. 31, 2018		75,501,394
Balance at Dec. 31, 2018		$ 75	$ 414,001	$ (406,924)	$ 7,152

Consolidated Statements Of Ch_2

Consolidated Statements Of Changes In Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Common Stock [Member] | Private Placement [Member]
Stock and warrants issued, issuance costs		$ 470
Common Stock [Member] | Exercise Of Warrants [Member]
Stock and warrants issued, issuance costs		$ 220
Common Stock [Member] | Public Offering Of Common Stock [Member]
Stock and warrants issued, issuance costs	$ 1,008
Preferred Stock [Member] | Public Offering Of Preferred Stock [Member]
Stock and warrants issued, issuance costs	$ 504

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (11,371)	$ (10,497)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	675	786
Stock-based compensation expense	1,101	1,439
Loss on sale and disposal of property and equipment	11	4
Changes in operating assets and liabilities:
Accounts receivable	(81)	70
Prepaid expenses and other assets	(92)	28
Inventories	10	(9)
Accounts payable, accrued liabilities and other liabilities	380	50
Net cash used in operating activities	(9,367)	(8,129)
Cash flows from investing activities:
Purchase of property and equipment	(113)	(60)
Net cash used in investing activities	(113)	(60)
Cash flows from financing activities:
Proceeds from private placement offering of common stock and warrants, net of issuance costs		5,127
Proceeds from exercise of common stock warrants, net of issuance costs		3,576
Proceeds from public offering of preferred stock, net of issuance costs	4,496
Proceeds from public offering of common stock, net of issuance costs	8,990
Principal repayment of DECD loan	(185)	(183)
Repayment of capital lease obligations	(29)	(34)
Proceeds from issuance of common stock from exercise of stock options	29
Net cash provided by financing activities	13,301	8,486
Net increase in cash and cash equivalents	3,821	297
Cash and cash equivalents, beginning of year	5,539	5,242
Cash and cash equivalents, end of year	9,360	5,539
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	44	47
Supplemental disclosure of non-cash investing and financing activities:
Deemed dividend on warrant repricing		$ 942

Basis Of Presentation And Summa

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	12 Months Ended
	Dec. 31, 2018
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	NOTE 1: Basis of Presentation and Summary of Significant Accounting and Reporting Policies Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells the OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa”). Until August 2015, the Company distributed OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 3). Since August 2015, the Company has distributed all tests through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which was formed in April 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. ASPiRA IVD was built around a core of laboratory expertise and a United States Food and Drug Administration (“FDA”)-compliant quality system, and strives to deliver accurate and reliable results to its third-party customers suitable for FDA submission.  Liquidity As discussed in Note 6, on March 22, 2016, the Company entered into a loan agreement, as amended (the “Loan Agreement”), pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (“DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty. On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Aggregate gross proceeds of the private placement were approximately $5,597,000 (approximately $5,127,000 net of transaction costs). The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share. The warrants expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . As discussed in Note 7, on August 31, 2017, certain investors exercised outstanding warrants to purchase shares of Vermillion common stock for net proceeds of approximately $3,576,000 after deducting offering expenses. As discussed in Note 7, on April 17, 2018, the Company completed two public offerings, pursuant to which certain investors purchased Vermillion common stock and Vermillion Series B convertible preferred stock for net proceeds of approximately $13,500,000 after deducting offering expenses. The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $406,924,000 at December 31, 2018. The Company expects to incur a net loss in 2019 as well. The Company’s management believes that successful achievement of the business objectives will require additional financing. The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, public and private equity offerings, debt financing, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product and ASPiRA IVD sales to be the Company’s only material, recurring source of cash in 2019. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation . Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.  Fair Value Measurement Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 , but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities. Accounts receivable Virtually all accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customer’s financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable. Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized. Revenue Recognition Product Revenue: Prior to January 1, 2018, the Company recognized product revenue in accordance with the provisions of ASC 954-605, Health Care Entities - Revenue Recognition. The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of the test result to the prescribing physician. The entire transaction price is allocated to the single performance obligation contained in a contract with a patient. Under the previous revenue recognition accounting methodology, certain product revenue was recognized upon the ultimate receipt of cash. Under ASC 606, all revenue is recognized upon completion of the OVA1 or Overa test based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The Company also reviewed its patient account population and determined an appropriate distribution of patient accounts by payer ( i.e. , Medicare, patient pay, other third-party payer, etc .) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. There were no impairment losses on accounts receivable recorded during the year ended December 31, 2018.Under the modified retrospective implementation method, the Company recorded a one-time cumulative effect adjustment at January 1, 2018 to reflect the aggregate effect of all open OVA1 and Overa tests performed prior to January 1, 2018 as if revenue had been recognized under ASC 606. The cumulative effect adjustment was recorded increasing the opening balance of Accounts Receivable by $500,000 in the condensed consolidated balance sheets with an offsetting reduction to Accumulated Deficit. The Company’s right to receive payment on this balance is contingent only on the passage of time.  The following tables show the impact of adoption to our consolidated statement of operations and balance sheet:    Twelve Months Ended December 31, 2018  Impact of changes in accounting policies  (in thousands, except per share amounts) As Reported Balances without adoption of ASC 606 Effect of Change Higher/(Lower)  Product revenue $ 2,772 $ 2,731 $ 41  Operating loss $ (11,333) $ (11,374) $ 41  Net loss $ (11,371) $ (11,412) $ 41  Net loss per share, basic and diluted $ (0.16) $ (0.16) $ -    December 31, 2018  Impact of changes in accounting policies  (in thousands) As Reported Balances without adoption of ASC 606 Effect of Change Higher/(Lower)  Assets:  Accounts receivable $ 786 $ 245 $ 541  Stockholders' equity:  Accumulated deficit $ (406,924) $ (407,465) $ 541  ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s consolidated statement of cash flows, as reflected in the above tables.  Other Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses. Service Revenue: The Company’s service revenue is generated by performing IVD trial services for third-party customers. Application of the modified retrospective method did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company has not disclosed the value of unsatisfied performance obligations for all service revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The remainder are not material to the consolidated financial statements. Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established. Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $219,000 and $258,000 for the years ended December 31, 2018 and 2017, respectively. Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan, as amended (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. The Company uses the straight line method to amortize the fair value over the vesting period of the award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption . The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company uses the straight-line method to amortize the fair value over the vesting period of the award. The Company records stock-based compensation net of estimated forfeitures. The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options is recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another. Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated . Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates. Income Taxes The Company accounts for income taxes using the liability method. Under this method , deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Accounting for Uncertainty in Income Taxes c larifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets. The Tax Cuts and Jobs Act (H.R. 1), was enacted on December 22, 2017. ASC740, Accounting for Income Taxes , requires companies to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions is for tax years beginning after December 31, 2017. Since the Company’s federal deferred tax asset was fully offset by a valuation allowance, the reduction in the U.S. corporate income tax rate to 21% did not materially affect the Company’s financial statements. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share. Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt are at cost, which approximates fair value due to the short maturity of those instruments. The carrying value of debt approximates fair value due to its interest rate approximating market rates of interest available to the Company for similar instruments. Segment Reporting The Company’s chief operating decision maker evaluates the business on a consolidated basis and therefore, the Company operates one reportable segment.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2018
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	 NOTE 2: Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718), Compensation - Stock Compensation (“ASU 2016-09”). The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The Company adopted this standard on January 1, 2018, and the adoption did not have a material impact on the consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Base Payment Accounting. This new guidance expands the scope of Topic 718 to include share-based payment transactions from acquiring goods and services from nonemployees, which was previously codified under Topic 505, where this change will modify the measurement requirements of nonemployee awards. This amendment is effective for annual periods after December 15, 2018. The Company is currently evaluating the impact of adoption of this standard. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. The ASU is scheduled to be effective in 2020. The Company is currently assessing the impact of this ASU on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Subsequently, in July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which provides a number of optional practical expedients in transition. The Company adopted ASU 2016-02 effective January 1, 2019 and elected the package of practical expedients and the new transition approach permitted by ASU 2018-11. ASU 2018-11 allows the Company not to reassess existing identification of leases, classification of leases or any initial direct costs. T he Company has also elected to use the hindsight practical expedient. The Company has two office leases which are required to be recorded as ROU assets and corresponding lease liabilities on the balance sheet. The Company has no short term leases with terms of less than twelve months. The Company expects to recognize ROU assets and a lease liability of less than $ 200,000 related to its leases on its consolidated balance sheet as of January 1, 2019. The Company will no t have a cumulative adjustment impacting retained earnings. In May 2014, the FASB issued ASC 606, which superseded existing revenue recognition guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 effective on January 1, 2018 using the modified retrospective method. Please see the above “Revenue Recognition” section for a discussion of the Company’s revenue recognition under ASC 606.  

Strategic alliance And Secured

Strategic alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	12 Months Ended
	Dec. 31, 2018
Strategic alliance And Secured Line Of Credit With Quest Diagnostics Incorporated [Abstract]
Strategic alliance And Secured Line Of Credit With Quest Diagnostics Incorporated	NOTE 3: Strategic Alliance And Secured Line Of Credit with Quest Diagnostics Incorporated In March 2015, the Company reached an agreement with Quest Diagnostics that terminated the previous Strategic Alliance Agreement with Quest Diagnostics. The Company also entered into a commercial agreement with Quest Diagnostics. Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 2015. Pursuant to this agreement, as amended as of March 1, 2018, Quest Diagnostics has continued to provide blood draw and logistics support by transporting specimens to ASPiRA LABS for testing in exchange for a market value fee. Per the terms of the commercial agreement, we may not offer to existing or future Quest Diagnostics customers CA 125-II or other tests that Quest Diagnostics offers. As of the date of this Annual Report on Form 10-K, we are in the process of renewing this agreemen . 

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2018
Property And Equipment [Abstract]
Property And Equipment	Note 4: Property and Equipment The components of property and equipment as of December 31, 2018 and 2017 were as follows :     December 31,  (in thousands) 2018 2017  Machinery and equipment $ 1,367 $ 1,400  Demonstration equipment 39 39  Computer equipment and software 1,109 1,055  Furniture and fixtures 137 120  Leasehold improvements 706 706  Gross property and equipment 3,358 3,320  Accumulated depreciation and amortization (2,750) (2,139)  Property and equipment, net $ 608 $ 1,181  Depreciation expense for property and equipment was $675,000 and $786,000 for the years ended December 31, 2018 and 2017, respectively. The accumulated amortization of assets under capital lease obligations was $232,000 and the net book value of assets under capital lease obligations was none as of December 31, 2018. The accumulated amortization of assets under capital lease obligations was $193,000 and the net book value of assets under capital lease obligations was $39,000 as of December 31, 2017.

Accured Liabilities

Accured Liabilities	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities [Abstract]
Accrued Liabilities	NOTE 5: Accrued Liabilities The components of accrued liabilities as of December 31, 2018 and 2017 were as follows:      December 31,  (in thousands) 2018 2017  Payroll and benefits related expenses $ 853 $ 867  Collaboration and research agreements expenses 366 358  Professional services 329 216  Other accrued liabilities 277 209  Total accrued liabilities $ 1,825 $ 1,650 

Commitments, Contingencies And

Commitments, Contingencies And Debt	12 Months Ended
	Dec. 31, 2018
Commitments, Contingencies And Debt [Abstract]
Commitments, Contingencies And Debt	NOTE 6: Commitments, Contingencies and debt As of December 31, 2018, the annual amounts of future minimum payments under certain of the Company’s contractual obligations are shown in the table below. Our operating leases consist of two office leases. The office leases require us to pay additional amounts for common area maintenance charges in addition to rent.      Payments Due by Period  (in thousands) Total 2019 2020 2021 2022 2023 Thereafter  Operating Leases $ 474 $ 278 $ 140 $ 56 $ - $ - $ -  Capital Leases - - - - - - -  Debt Obligations 1,621 221 221 221 221 221 516  Total $ 2,095 $ 499 $ 361 $ 277 $ 221 $ 221 $ 516   In addition, the Company has minimum royalty obligations (described below in non-cancelable collaboration obligations and other commitments) and minimum quantities of reagent purchases from the manufacturer of certain laboratory instruments. Development Loan On March 22, 2016, the Company entered into the Loan Agreement with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. Proceeds from the loan were utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company’s Trumbull, Connecticut facility and operations. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender. Under the terms of the Loan Agreement, as amended, the Company may be eligible for forgiveness of up to $2,000,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2021 (the “Measurement Date”). Conversely, if the Company is either unable to meet these job creation and retention milestones, namely, hiring and retaining for a consecutive two-year period 40 full-time employees with a specified average annual salary by the Measurement Date and retaining those employees for a two year period or does not maintain the Company’s Connecticut operations for a period of 10 years, the DECD may require early repayment of a portion or all of the loan depending on job attainment as compared to the required amount plus a penalty of 5% of the total funded l oan . An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement . The Agreement provides that the remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty . The balance of the DECD loan was $1,481,000 and $1,666,000 at December 31, 2018 and 2017, respectively. Operating Leases The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease, including its principal facility and CLIA laboratory located in Austin, Texas. As of December 31, 2018 the Company’s Austin, Texas lease included an annual base rent of $86,000 and annual estimated common area charges, taxes and insurance of $55,000 . The lease expires on January 31, 2020 . The Company’s Trumbull, Connecticut lease includes an aggregate annual base rent of $32,000 and annual estimated common area charges, taxes and insurance of $95,000 . The lease expires on June 8, 2021 . Rental expense under operating leases for the years ended December 31, 2018 and 2017 totaled $265,000 and $254,000 , respectively. Non-cancelable Collaboration Obligations and Other Commitments The Company had a research collaboration agreement with The Johns Hopkins University School of Medicine (“JHU”) directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human diseas e. This agreement expired on March 31, 2016. There were no collaboration expenses under the JHU collaboration agreement for the year s ended December 31, 2018 and December 31, 2017. Under the terms of the amended license agreement dated September 19, 2016, Vermillion is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500 . Royalty expense for the years ended December 31, 2018 and 2017 totaled $120,000 and $116,000 , respectively. Contingent Liabilities From time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations. The Company establishes reserves for specific liabilities in connection with legal actions that management deems to be probable and estimable. The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2018
Common Stock [Abstract]
Common Stock	NOTE 7: Common Stock 2018 Offerings On April 13, 2018, the Company entered into two underwriting agreements (each, an “Underwriting Agreement”) with Piper Jaffray & Co., as the sole underwriter (the “Underwriter”), in connection with separate but concurrent public offerings of the Company’s securities. Pursuant to the first Underwriting Agreement, the Company agreed to issue and sell an aggregate of 10,000,000 shares of Vermillion common stock, par value $0.001 per share, offered by the Underwriter in a public offering at a price to the public of $1.00 per share (the “Common Stock Offering”). Under this Underwriting Agreement, the Company granted the Underwriter an option to purchase up to an additional 1,500,000 shares of Vermillion common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. The Underwriter did not exercise this option. The Common Stock Offering closed on April 17, 2018 and resulted in proceeds, net of 7% underwriting costs and other offering costs, to the Company of $8,992,000 . Pursuant to the second Underwriting Agreement, the Company agreed to issue and sell an aggregate of 50,000 shares of Vermillion Series B Convertible Preferred Stock, par value $0.001 per share, offered by the Underwriter in a public offering at a price to the public of $100.00 per share (the “Series B Offering”). The Series B Offering closed on April 17, 2018 and resulted in proceeds, net of 7% underwriting costs and other offering costs, to the Company of $4,496,000 . Upon obtaining Company stockholder approval at the annual meeting of Company stockholders on June 21, 2018, each of the 50,000 shares of Vermillion Series B Convertible Preferred Stock was automatically converted into shares of Vermillion common stock, at a conversion rate of 100 shares of Vermillion common stock per one share of Vermillion Series B Convertible Preferred Stock, including shares issuable pursuant to customary anti-dilution provisions. 2017 Private Placement On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Net proceeds of the private placement were approximately $5,127,000 after deducting offering expenses. The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share. The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . The sale of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is $804,000 and to the common stock is approximately $4,323,000 . Stock holder s Agreement In connection with a private placement offering of common stock and warrants the Company completed in May 2013, the Company entered into a stockholders agreement which, among other things, gives two of the primary investors in that offering the right to participate in any future equity offerings by the Company on the same price and terms as other investors. In addition, th is stockholders agreement prohibits the Company from taking certain material actions without the consent of at least one of the two primary investors in that offering. These material actions include: · Making any acquisition with a value greater than $2 million; · Offering, selling or issuing any securities senior to Vermillion’s common stock or any securities that are convertible into or exchangeable or exercisable for securities ranking senior to Vermillion’s common stock; · Taking any action that would result in a change in control of the Company or an insolvency event; and · Paying or declaring dividends on any securities of the Company or distributing any assets of the Company other than in the ordinary course of business or repurchasing any outstanding securities of the Company. The foregoing rights terminate for each stockholder when that stockholder ceases to beneficially own less than 50% of the shares and warrants (taking into account shares issued upon exercise of the warrants), in the aggregate, that were purchased at the closing of the 2013 private placement. Warrants Warrants outstanding as of December 31, 2018 and 2017 were as follows:     Exercise Price Number of Shares Outstanding under Warrant  Issuance Date Expiration Date per Share December 31, 2018 December 31, 2017  February 17, 2017 February 17, 2022 $ 1.80 2,810,338 2,810,338  2,810,338 2,810,338   

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2018
Loss Per Share [Abstract]
Loss Per Share	NOTE 8: Loss Per Share The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December 31, 2018 and 2017 was as follows:    Loss Shares Per Share  (In thousands, except per share data) (Numerator) (Denominator) Amount  Year ended December 31, 2017:  Net loss $ (10,497)  Deemed dividend on warrant repricing (942)  Net loss available to common shareholders - basic (11,439) 56,943,596 $ (0.20)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (11,439) 56,943,596 $ (0.20)    Year ended December 31, 2018:  Net loss available to common shareholders - basic $ (11,371) 70,085,842 $ (0.16)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (11,371) 70,085,842 $ (0.16)  Due to net losses for the years ended December 31, 2018 and 2017, diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential shares of common stock that are antidilutive. The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December 31, 2018 and 2017 were as follows:     Year Ended December 31,  2018 2017  Stock options 4,612,005 4,219,568  Stock warrants 2,810,338 2,810,338  Unvested restricted stock awards 11,667 1,704  Potential common shares 7,434,010 7,031,610 

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2018
Employee Benefit Plans [Abstract]
Employee Benefit Plans	NOTE 9: Employee Benefit Plans 2000 Stock Plan Under the Amended and Restated 2000 Stock Plan (the “2000 Plan”), options could be granted at prices not lower than 85% and 100% of the fair market value of the common stock for non-statutory and statutory stock options, respectively. Options generally vest monthly over a period of four years and unexercised options generally expire ten years from the date of grant. The authority of Vermillion’s Board of Directors to grant new stock options and awards under the 2000 Plan terminated in 2010. There were no stock options under the 2000 Stock Plan exercised during the years ended December 31, 2018 or 2017. All remaining options expired during 2018. No additional shares of common stock were reserved for future option grants under the 2000 Plan. 2010 Stock Incentive Plan Under the 2010 Plan, employees, directors and consultants of the Company are eligible to receive awards. The 2010 Plan is administered by the Compensation Committee of Vermillion’s Board of Directors. The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. In June 2015 and June 2018, Vermillion’s stockholders approved increases of 4,500,000 and 4,000,000 , respectively, in the number of shares available for issuance under the 2010 Plan for a total of 12,122,983 shares. Unexercised options generally expire ten years from the date of grant. Options to purchase 32,500 shares of common stock were exercised during the year ended December 31, 2018. There were no options exercised during the year ended December 31, 2017. During the year ended December 31, 2018, Vermillion issued to Vermillion’s Board of Directors an aggregat e of 398,400 shares of restricted stock under the 2010 Plan having a fair value of $442,000 as payment for services rendered in 2018. 35,000 of those shares of restricted stock were forfeited upon the departure of a board member in June. The Company also issued to certain consultants 40,606 shares of restricted stock under the 2010 Plan having a fair value of $32,000 . During the year ended December 31, 2017, Vermillion issued to Vermillion’s Board of Directors 131,250 shares of restricted stock under the 2010 Plan having a fair value of $281,000 as payment for services rendered in 2017. The Company also issued to certain consultants 32,332 shares of restricted stock under the 2010 Plan having a fair value of $54,000 . The activity related to shares available for grant under the 2000 Plan and the 2010 Plan for the years ended December 31, 2018 and 2017 was as follows:     2000 Stock Plan 2010 Stock Option Plan Total  Shares available at December 31, 2016 - 2,989,760 2,989,760  Options canceled 3,050 776,455 779,505  Reduction in shares reserved (3,050) - (3,050)  Options granted - (1,548,000) (1,548,000)  Restricted stock units granted - (163,582) (163,582)  Shares available at December 31, 2017 - 2,054,633 2,054,633  Shares added - 4,000,000 4,000,000  Options canceled 18,000 861,063 879,063  Reduction in shares reserved (18,000) - (18,000)  Options granted - (1,304,000) (1,304,000)  Restricted stock units granted - (432,877) (432,877)  Shares available at December 31, 2018 - 5,178,819 5,178,819   The stock option activity under the 2000 Plan and 2010 Plan for the years ended December 31, 2018 and 2017 was as follows:    Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term  Options outstanding at December 31, 2016 3,451,073 $ 1.70 $ 41 8.46  Granted 1,548,000 2.05  Exercised - -  Canceled (779,505) 1.51  Options outstanding at December 31, 2017 4,219,568 $ 1.86 $ 1,033 8.02  Granted 1,304,000 0.98  Exercised (32,500) 0.89  Canceled (879,063) 1.58  Options outstanding at December 31, 2018 4,612,005 $ 1.67 $ - 7.17   Shares exercisable:  December 31, 2018 2,391,760 $ 1.94 $ - 5.72  Shares expected to vest:  December 31, 2018 1,820,601 $ 1.39 $ - 8.74   The range of exercise prices for options outstanding and exercisable at December 31, 2018 is as follows:     Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price  $ 0.01 - $ 1.30 1,386,687 $ 0.97 8.78 210,687 $ 1.01  1.31 - 1.64 1,249,668 1.49 6.83 846,042 1.49  1.65 - 2.08 852,500 1.99 4.31 714,381 1.99  2.09 - 11.55 1,123,150 3.29 5.58 620,650 2.79   $ 0.01 - $ 11.55 4,612,005 $ 1.67 7.17 2,391,760 $ 1.94       (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested Options  Year ended December 31, 2018 $ 9 $ 2,319  Year ended December 31, 2017 $ - $ 2,272   Stock-based Compensation Employee Stock-based Compensation Expense The Company records stock-based compensation net of estimated forfeitures. The assumptions used to calculate the fair value of options granted under the 2010 Plan that were incorporated in the Black-Scholes pricing model for the years ended December 31, 2018 and 2017 were as follows:      Year Ended December 31,  2018 2017  Dividend yield - % - %  Volatility 69 % 69 %  Risk-free interest rate 2.69 % 1.77 %  Expected lives (years) 4.0 4.0  Weighted average grant date fair value $ 0.51 $ 1.11  The allocation of employee stock-based compensation expense by functional area for the years ended December 31, 2018 and 2017 was as follows:     Year Ended December 31,  (in thousands) 2018 2017  Cost of sales $ 91 $ 82  Research and development 6 6  Sales and marketing 112 150  General and administrative 982 914  Total $ 1,191 $ 1,152  As of December 31, 2018, total unrecognized compensation cost related to unvested stock option awards was approximately $1,540,000 and the related weighted average period over which it is expected to be recognized was 2.65 years. 401(k) Plan The Company’s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0% of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit. The Company is not required to make contributions under the 401(k) Plan. During the years ended December 31, 2018 and 2017, the Company did no t contribute to the 401(k) Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Income Taxes	NOTE 10: Income Taxes There was no income tax expense or benefit for the years ended December 31, 2018 or 2017 because of net losses during those years. These net losses were generated from domestic operations.  Based on the available objective evidence and uncertainty about the timing and amount of any future profits, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2018 and 2017. The components of net deferred tax assets at December 31, 2018 and 2017 were as follows:      Year Ended December 31,  (in thousands) 2018 2017  Deferred tax assets:  Net operating losses $ 20,614 $ 17,768  Amortization - R&D intangibles 2,410 3,091  Other 2,406 2,461  Total deferred tax assets 25,430 23,320  Valuation allowance (25,430) (23,320)  Deferred tax assets $ - $ -   Deferred tax liabilities:  Other $ - $ -  Deferred tax liabilities $ - $ -   Net deferred tax asset $ - $ -   The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 2018 and 2017 was as follows:      Year Ended December 31,  2018 2017  Tax at federal statutory rate 21 % 34 %  State tax, net of federal benefit 1 1  Valuation allowance (19) 74  Permanent items - (2)  Change in Federal Tax Rate (2017 Tax Reform) 2 (111)  Other (5) 4  Effective income tax rate - % - %  As a result of the Tax Cuts and Jobs Act of 2017, net operating losses (“ NOLs ”) arising before January 1, 2018, and NOLs arising after January 1, 2018, are subject to different rules. The Company’s pre-2018 NOLs will expire in varying amounts from 2023 through 2037, if not utilized and can offset 100% of future taxable income for regular tax purposes. Any NOLs arising after January 1, 2018 can generally be carried forward indefinitely and can offset up to 80% of future taxable income. The Company’s ability to use its NOLs during this period will be dependent on its ability to generate taxable income, and the NOLs could expire before the Company generate s sufficient taxable income . The Company’s ability to use net operating loss carryforwards may be restricted due to ownership change limitations occurring in the past or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), as well as similar state provisions. These ownership changes may also limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company’s management believes that Section 382 ownership changes occurred as a result of the Company’s follow-on public offerings in 2011, 2013 and 2015. Any limitation may result in the expiration of a portion of the net operating loss carryforwards before utilization and any net operating loss carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the Company’s valuation allowance . Due to the existence of a valuation allowance, it is not expected that such limitations, if any, will have an impact on the Company’s results of operations or financial position. Legislation commonly referred to as the Tax Cuts and Jobs Act (H.R. 1) was enacted on December 22, 2017. ASC740, Accounting for Income Taxes , requires companies to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions is for tax years beginning after December 31, 2017. Since the Company’s federal deferred tax asset was fully offset by a valuation allowance, the reduction in the U.S. corporate income tax rate to 21% did not materially affect the Company’s financial statements. Provisional amounts Deferred tax assets and liabilities: Certain domestic-related deferred tax assets and liabilities were remeasured based on the rates at which they are expected to reverse in the future, which is generally 21 percent. As a valuation allowance is recorded for the full amount of these deferred tax assets and liabilities, the remeasurement of the deferred tax assets and liabilities was offset by a corresponding remeasurement of the valuation allowance. Company management believes that it is more likely than not that the benefit from certain deferred tax assets will not be realized due to the history of the Company’s operating losses. In recognition of this risk, the Company has provided a valuation allowance on the deferred tax assets relating to these assets. The valuation allowance was approximately $25,000,000 and $23,000,000 at December 31, 2018 and 2017, respectively. The increase of $2,000,000 between 2017 and 2018 is primarily due to adjustments to the domestic deferred tax assets related to the net operating losses. The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2018, the Company’s federal returns for the years ended 2015 through the current period and most state returns for the years ended 2014 through the current period are still open to examination. In addition, all of the net operating loss carryforwards and research and development credits generated in years earlier than 2015 and 2014, respectively, are still subject to Internal Revenue Service audit. The federal and California tax returns for the year ended December 31, 2017 reflect research and development carryforwards of $5,621,000 and $5,312,000 , respectively. The Company has recognized additional deferred tax assets for federal and California research and development credits of $16,000 and $18,000 for the year ended December 31, 2018, respectively. As of December 31, 2018, the Company’s gross unrecognized tax benefits are approximately $10,967,000 which are attributable to research and development credit carryforwards. A reconciliation of the change in the Company’s unrecognized tax benefits is as follows:     (in thousands) Federal Tax State Tax Total  Balance at December 31, 2016 $ 5,430 $ 5,317 $ 10,747  Increase in tax position during 2017 46 35 81  Decrease due to expirations - - -  Balance at December 31, 2017 $ 5,476 $ 5,352 $ 10,828  Return to provision true up 145 (40) 105  Increase in tax position during 2018 16 18 34  Decrease due to expirations - - -  Balance at December 31, 2018 $ 5,637 $ 5,330 $ 10,967  The increase for the year ended December 31, 2018 relates to a position taken in the current year. The increase for the year ended December 31, 2017 is related to tax positions taken during 2017 and prior years. If the $10,967,000 of unrecognized income tax benefit is recognized, approximately $10,967,000 would impact the effective tax rate in the period in which each of the benefits is recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations and comprehensive loss. The Company has not recorded any interest or penalties as a result of uncertain tax positions as of December 31, 2018 and 2017. Accrued interest and penalties would be included within the related liability in the consolidated balance sheet.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 11: Related Party Transactions On December 18, 2017, the Company entered into a consulting agreement for a term of up to five months with the Company’s former Senior Vice President, Finance and Chief Accounting Officer. Pursuant to the terms of the consulting agreement through May 15, 2018, the consultant provided accounting and finance services related to the transition of financial leadership. The Company agreed to pay $150 per hour for such consulting services. The consultant also remained eligible for payout under the Company’s 2017 Corporate Incentive Plan after he satisfactorily met certain performance obligations as outlined in the consulting agreement. During the year ended December 31, 2018, the consultant was paid an aggregate of $53,925 for services provided pursuant to the consulting agreement.

Basis Of Presentation And Sum_2

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Policy)	12 Months Ended
	Dec. 31, 2018
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells the OVA1™ and Overa™ risk of malignancy tests for ovarian cancer (“OVA1” and “Overa”). Until August 2015, the Company distributed OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 3). Since August 2015, the Company has distributed all tests through Vermillion’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”). The Company also offers in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which was formed in April 2016. ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. ASPiRA IVD was built around a core of laboratory expertise and a United States Food and Drug Administration (“FDA”)-compliant quality system, and strives to deliver accurate and reliable results to its third-party customers suitable for FDA submission.
Liquidity	Liquidity As discussed in Note 6, on March 22, 2016, the Company entered into a loan agreement, as amended (the “Loan Agreement”), pursuant to which it may borrow up to $4,000,000 from the State of Connecticut Department of Economic and Community Development (“DECD”). An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. The remaining $2,000,000 will be advanced if and when the Company achieves certain other future milestones. The loan may be prepaid at any time without premium or penalty. On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased 3,747,125 shares of Vermillion common stock at a price of $1.40 per share. Vermillion also issued warrants to purchase shares of common stock at a price of $0.125 per warrant share in the private placement. Aggregate gross proceeds of the private placement were approximately $5,597,000 (approximately $5,127,000 net of transaction costs). The warrants are exercisable for 2,810,338 shares of Vermillion common stock at $1.80 per share. The warrants expire on the fifth anniversary of the date of issuance or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period . As discussed in Note 7, on August 31, 2017, certain investors exercised outstanding warrants to purchase shares of Vermillion common stock for net proceeds of approximately $3,576,000 after deducting offering expenses. As discussed in Note 7, on April 17, 2018, the Company completed two public offerings, pursuant to which certain investors purchased Vermillion common stock and Vermillion Series B convertible preferred stock for net proceeds of approximately $13,500,000 after deducting offering expenses. The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $406,924,000 at December 31, 2018. The Company expects to incur a net loss in 2019 as well. The Company’s management believes that successful achievement of the business objectives will require additional financing. The Company expects to raise capital through a variety of sources, which may include the exercise of common stock warrants, public and private equity offerings, debt financing, collaborations, licensing arrangements, grants and government funding and strategic alliances. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on the business, results of operations and financial condition. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. Management expects cash from product and ASPiRA IVD sales to be the Company’s only material, recurring source of cash in 2019. Given the above conditions, there is substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties.
Basis Of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation
Use Of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.
Cash And Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.
Fair Value Measurement	Fair Value Measurement Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
Concentration Of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 , but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.
Accounts Receivable	Accounts receivable Virtually all accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customer’s financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable.
Property And Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.
Revenue Recognition	Revenue Recognition Product Revenue: Prior to January 1, 2018, the Company recognized product revenue in accordance with the provisions of ASC 954-605, Health Care Entities - Revenue Recognition. The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of the test result to the prescribing physician. The entire transaction price is allocated to the single performance obligation contained in a contract with a patient. Under the previous revenue recognition accounting methodology, certain product revenue was recognized upon the ultimate receipt of cash. Under ASC 606, all revenue is recognized upon completion of the OVA1 or Overa test based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any current developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year. The Company also reviewed its patient account population and determined an appropriate distribution of patient accounts by payer ( i.e. , Medicare, patient pay, other third-party payer, etc .) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. There were no impairment losses on accounts receivable recorded during the year ended December 31, 2018.Under the modified retrospective implementation method, the Company recorded a one-time cumulative effect adjustment at January 1, 2018 to reflect the aggregate effect of all open OVA1 and Overa tests performed prior to January 1, 2018 as if revenue had been recognized under ASC 606. The cumulative effect adjustment was recorded increasing the opening balance of Accounts Receivable by $500,000 in the condensed consolidated balance sheets with an offsetting reduction to Accumulated Deficit. The Company’s right to receive payment on this balance is contingent only on the passage of time.  The following tables show the impact of adoption to our consolidated statement of operations and balance sheet:    Twelve Months Ended December 31, 2018  Impact of changes in accounting policies  (in thousands, except per share amounts) As Reported Balances without adoption of ASC 606 Effect of Change Higher/(Lower)  Product revenue $ 2,772 $ 2,731 $ 41  Operating loss $ (11,333) $ (11,374) $ 41  Net loss $ (11,371) $ (11,412) $ 41  Net loss per share, basic and diluted $ (0.16) $ (0.16) $ -    December 31, 2018  Impact of changes in accounting policies  (in thousands) As Reported Balances without adoption of ASC 606 Effect of Change Higher/(Lower)  Assets:  Accounts receivable $ 786 $ 245 $ 541  Stockholders' equity:  Accumulated deficit $ (406,924) $ (407,465) $ 541  ASC 606 did not have an aggregate impact on the Company’s net cash provided by operating activities, but resulted in offsetting changes in certain assets and liabilities presented within net cash provided by operating activities in the Company’s consolidated statement of cash flows, as reflected in the above tables.  Other Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses. Service Revenue: The Company’s service revenue is generated by performing IVD trial services for third-party customers. Application of the modified retrospective method did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company has not disclosed the value of unsatisfied performance obligations for all service revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The remainder are not material to the consolidated financial statements.
Research And Development Costs	Research and Development Costs Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.
Patent Costs	Patent Costs Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $219,000 and $258,000 for the years ended December 31, 2018 and 2017, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company records the fair value of non-cash stock-based compensation costs for stock options and stock purchase rights related to the Amended and Restated 2010 Stock Incentive Plan, as amended (the “2010 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. The Company uses the straight line method to amortize the fair value over the vesting period of the award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment. The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption . The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company uses the straight-line method to amortize the fair value over the vesting period of the award. The Company records stock-based compensation net of estimated forfeitures. The Company also records the fair value of non-cash stock-based compensation costs for equity instruments issued to non-employees. The cost for these options is recalculated each reporting period using a Black-Scholes option valuation model. A change in assumptions used in the calculations, including changes in the fair value of common stock, can result in significant changes in the amounts recorded from one reporting period to another.
Contingencies	Contingencies The Company accounts for contingencies in accordance with ASC 450 Contingencies ("ASC 450") which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated . Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
Income Taxes	Income Taxes The Company accounts for income taxes using the liability method. Under this method , deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized. ASC Topic 740, Accounting for Uncertainty in Income Taxes c larifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets. The Tax Cuts and Jobs Act (H.R. 1), was enacted on December 22, 2017. ASC740, Accounting for Income Taxes , requires companies to recognize the effect of tax law changes in the period of enactment even though the effective date for most provisions is for tax years beginning after December 31, 2017. Since the Company’s federal deferred tax asset was fully offset by a valuation allowance, the reduction in the U.S. corporate income tax rate to 21% did not materially affect the Company’s financial statements.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt are at cost, which approximates fair value due to the short maturity of those instruments. The carrying value of debt approximates fair value due to its interest rate approximating market rates of interest available to the Company for similar instruments.
Segment Reporting	Segment Reporting The Company’s chief operating decision maker evaluates the business on a consolidated basis and therefore, the Company operates one reportable segment.

Basis Of Presentation And Sum_3

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Summary Of The Impact Of Adoption ASC 606 On Financials	  Twelve Months Ended December 31, 2018  Impact of changes in accounting policies  (in thousands, except per share amounts) As Reported Balances without adoption of ASC 606 Effect of Change Higher/(Lower)  Product revenue $ 2,772 $ 2,731 $ 41  Operating loss $ (11,333) $ (11,374) $ 41  Net loss $ (11,371) $ (11,412) $ 41  Net loss per share, basic and diluted $ (0.16) $ (0.16) $ -    December 31, 2018  Impact of changes in accounting policies  (in thousands) As Reported Balances without adoption of ASC 606 Effect of Change Higher/(Lower)  Assets:  Accounts receivable $ 786 $ 245 $ 541  Stockholders' equity:  Accumulated deficit $ (406,924) $ (407,465) $ 541 

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property And Equipment [Abstract]
Components Of Property And Equipment	   December 31,  (in thousands) 2018 2017  Machinery and equipment $ 1,367 $ 1,400  Demonstration equipment 39 39  Computer equipment and software 1,109 1,055  Furniture and fixtures 137 120  Leasehold improvements 706 706  Gross property and equipment 3,358 3,320  Accumulated depreciation and amortization (2,750) (2,139)  Property and equipment, net $ 608 $ 1,181 

Accurued Liabilities (Tables)

Accurued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities [Abstract]
Components Of Accrued Liabilities	   December 31,  (in thousands) 2018 2017  Payroll and benefits related expenses $ 853 $ 867  Collaboration and research agreements expenses 366 358  Professional services 329 216  Other accrued liabilities 277 209  Total accrued liabilities $ 1,825 $ 1,650 

Commitments, Contingencies An_2

Commitments, Contingencies And Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments, Contingencies And Debt [Abstract]
Summary Of Commitments, Contingencies And Debt	   Payments Due by Period  (in thousands) Total 2019 2020 2021 2022 2023 Thereafter  Operating Leases $ 474 $ 278 $ 140 $ 56 $ - $ - $ -  Capital Leases - - - - - - -  Debt Obligations 1,621 221 221 221 221 221 516  Total $ 2,095 $ 499 $ 361 $ 277 $ 221 $ 221 $ 516   

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2018
Common Stock [Abstract]
Schedule Of Warrants Outstanding	   Exercise Price Number of Shares Outstanding under Warrant  Issuance Date Expiration Date per Share December 31, 2018 December 31, 2017  February 17, 2017 February 17, 2022 $ 1.80 2,810,338 2,810,338  2,810,338 2,810,338  

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Loss Per Share [Abstract]
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share	   Loss Shares Per Share  (In thousands, except per share data) (Numerator) (Denominator) Amount  Year ended December 31, 2017:  Net loss $ (10,497)  Deemed dividend on warrant repricing (942)  Net loss available to common shareholders - basic (11,439) 56,943,596 $ (0.20)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (11,439) 56,943,596 $ (0.20)    Year ended December 31, 2018:  Net loss available to common shareholders - basic $ (11,371) 70,085,842 $ (0.16)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (11,371) 70,085,842 $ (0.16) 
Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation	   Year Ended December 31,  2018 2017  Stock options 4,612,005 4,219,568  Stock warrants 2,810,338 2,810,338  Unvested restricted stock awards 11,667 1,704  Potential common shares 7,434,010 7,031,610 

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2018
Employee Benefit Plans [Abstract]
Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan	   2000 Stock Plan 2010 Stock Option Plan Total  Shares available at December 31, 2016 - 2,989,760 2,989,760  Options canceled 3,050 776,455 779,505  Reduction in shares reserved (3,050) - (3,050)  Options granted - (1,548,000) (1,548,000)  Restricted stock units granted - (163,582) (163,582)  Shares available at December 31, 2017 - 2,054,633 2,054,633  Shares added - 4,000,000 4,000,000  Options canceled 18,000 861,063 879,063  Reduction in shares reserved (18,000) - (18,000)  Options granted - (1,304,000) (1,304,000)  Restricted stock units granted - (432,877) (432,877)  Shares available at December 31, 2018 - 5,178,819 5,178,819  
Stock Option Activity Under 2000 Plan and 2010 Plan	   Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term  Options outstanding at December 31, 2016 3,451,073 $ 1.70 $ 41 8.46  Granted 1,548,000 2.05  Exercised - -  Canceled (779,505) 1.51  Options outstanding at December 31, 2017 4,219,568 $ 1.86 $ 1,033 8.02  Granted 1,304,000 0.98  Exercised (32,500) 0.89  Canceled (879,063) 1.58  Options outstanding at December 31, 2018 4,612,005 $ 1.67 $ - 7.17   Shares exercisable:  December 31, 2018 2,391,760 $ 1.94 $ - 5.72  Shares expected to vest:  December 31, 2018 1,820,601 $ 1.39 $ - 8.74 
Range of Exercise Prices for Options Outstanding and Exercisable	   Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price  $ 0.01 - $ 1.30 1,386,687 $ 0.97 8.78 210,687 $ 1.01  1.31 - 1.64 1,249,668 1.49 6.83 846,042 1.49  1.65 - 2.08 852,500 1.99 4.31 714,381 1.99  2.09 - 11.55 1,123,150 3.29 5.58 620,650 2.79   $ 0.01 - $ 11.55 4,612,005 $ 1.67 7.17 2,391,760 $ 1.94  
Fair Value of Options Vested	   (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested Options  Year ended December 31, 2018 $ 9 $ 2,319  Year ended December 31, 2017 $ - $ 2,272 
Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan	   Year Ended December 31,  2018 2017  Dividend yield - % - %  Volatility 69 % 69 %  Risk-free interest rate 2.69 % 1.77 %  Expected lives (years) 4.0 4.0  Weighted average grant date fair value $ 0.51 $ 1.11 
Allocation of Stock-Based Compensation Expense by Functional Area	   Year Ended December 31,  (in thousands) 2018 2017  Cost of sales $ 91 $ 82  Research and development 6 6  Sales and marketing 112 150  General and administrative 982 914  Total $ 1,191 $ 1,152 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Components Of Deferred Tax Assets (Liabilities)	   Year Ended December 31,  (in thousands) 2018 2017  Deferred tax assets:  Net operating losses $ 20,614 $ 17,768  Amortization - R&D intangibles 2,410 3,091  Other 2,406 2,461  Total deferred tax assets 25,430 23,320  Valuation allowance (25,430) (23,320)  Deferred tax assets $ - $ -   Deferred tax liabilities:  Other $ - $ -  Deferred tax liabilities $ - $ -   Net deferred tax asset $ - $ - 
Reconciliation Of Statutory Federal Income Tax Rate	   Year Ended December 31,  2018 2017  Tax at federal statutory rate 21 % 34 %  State tax, net of federal benefit 1 1  Valuation allowance (19) 74  Permanent items - (2)  Change in Federal Tax Rate (2017 Tax Reform) 2 (111)  Other (5) 4  Effective income tax rate - % - % 
Reconciliation Of Change In Unrecognized Tax Benefits	   (in thousands) Federal Tax State Tax Total  Balance at December 31, 2016 $ 5,430 $ 5,317 $ 10,747  Increase in tax position during 2017 46 35 81  Decrease due to expirations - - -  Balance at December 31, 2017 $ 5,476 $ 5,352 $ 10,828  Return to provision true up 145 (40) 105  Increase in tax position during 2018 16 18 34  Decrease due to expirations - - -  Balance at December 31, 2018 $ 5,637 $ 5,330 $ 10,967 

Basis Of Presentation And Sum_4

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Details)	Apr. 17, 2018USD ($)item	Aug. 31, 2017USD ($)	Feb. 17, 2017USD ($)$ / sharesshares	Apr. 15, 2016USD ($)	Dec. 31, 2018USD ($)segmentshares	Dec. 31, 2017USD ($)shares	Mar. 22, 2016USD ($)
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued | shares					75,501,394	60,036,017
Proceeds from issuance of private placement						$ 5,127,000
Warrants outstanding to purchase shares | shares					2,810,338	2,810,338
Proceeds from exercise of common stock warrants, net of issuance costs		$ 3,576,000				$ 3,576,000
Number of public offerings | item	2
Proceeds from public offering	$ 13,500,000
Accumulated deficit					(406,924,000)	(396,053,000)
Patent costs					$ 219,000	$ 258,000
Number of reportable segments | segment					1
Tax at federal statutory rate					21.00%	34.00%
Accounting Standards Update 2014-09 [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Cumulative effect of adjustment					$ 500,000
DECD [Member] | Line of Credit [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
DECD maximum borrowing capacity							$ 4,000,000
DECD initial disbursement				$ 2,000,000
DECD remaining borrowing capacity							$ 2,000,000
Private Placement [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued | shares			3,747,125
Sale of stock, price per share | $ / shares			$ 1.40
Issued a warrant to purchase common stock with a cost | $ / shares			$ 0.125
Proceeds from issuance of private placement			$ 5,597,000
Net proceeds from issuance of private placement			$ 5,127,000
Warrants outstanding to purchase shares | shares			2,810,338
Exercise price of warrants | $ / shares			$ 1.80
Minimum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life					3 years
Maximum [Member]
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life					5 years

Basis Of Presentation And Sum_5

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Summary Of The Impact Of Adoption ASC 606 On Financials) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 3,053	$ 3,121
Operating loss	(11,333)	(10,441)
Net loss	$ (11,371)	$ (10,497)
Net loss per share, basic and diluted	$ (0.16)	$ (0.20)
Assets
Accounts receivable	$ 786	$ 205
Stockholders' equity:
Accumulated deficit	(406,924)	(396,053)
Balances Without Adoption of ASC 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Operating loss	(11,374)
Net loss	$ (11,412)
Net loss per share, basic and diluted	$ (0.16)
Assets
Accounts receivable	$ 245
Stockholders' equity:
Accumulated deficit	(407,465)
Effect of Change Higher/(Lower) [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Operating loss	41
Net loss	41
Assets
Accounts receivable	541
Stockholders' equity:
Accumulated deficit	541
Product [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	2,772	$ 2,853
Product [Member] | Balances Without Adoption of ASC 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	2,731
Product [Member] | Effect of Change Higher/(Lower) [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue	$ 41

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Details) - Accounting Standards Update 2016-02 [Member]	Jan. 01, 2019USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of adjustment	$ 0
Subsequent Event [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use Assets	200,000
Operating lease liability	$ 200,000

Property And Equipment (Narrati

Property And Equipment (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation expense for property and equipment	$ 675	$ 786
Accumulated amortization	2,750	2,139
Net book value	608	1,181
Assets Under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Accumulated amortization	$ 232	193
Net book value		$ 39

Property And Equipment (Compone

Property And Equipment (Components Of Property And Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 3,358	$ 3,320
Accumulated depreciation and amortization	(2,750)	(2,139)
Property and equipment, net	608	1,181
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,367	1,400
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	39	39
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,109	1,055
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	137	120
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 706	$ 706

Accrued Liabilities (Components

Accrued Liabilities (Components Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities [Abstract]
Payroll and benefits related expenses	$ 853	$ 867
Collaboration and research agreements expenses	366	358
Professional services	329	216
Other accrued liabilities	277	209
Total accrued liabilities	$ 1,825	$ 1,650

Commitments, Contingencies An_3

Commitments, Contingencies And Debt (Narrative) (Details)	Apr. 15, 2016USD ($)	Dec. 31, 2018USD ($)agreementemployee	Dec. 31, 2017USD ($)	Mar. 22, 2016USD ($)
Commitments And Contingencies [Line Items]
Number of operating office leases | agreement		2
Operating leases rental expense		$ 265,000	$ 254,000
Royalty expense		120,000	116,000
Austin, Texas facility [Member]
Commitments And Contingencies [Line Items]
Annual base rent		86,000
Annual estimated common area charges, taxes and insurance		$ 55,000
Lease expiration date		Jan. 31, 2020
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Annual base rent		$ 32,000
Annual estimated common area charges, taxes and insurance		$ 95,000
Lease expiration date		Jun. 8, 2021
Johns Hopkins University School Of Medicine [Member]
Commitments And Contingencies [Line Items]
Percent of royalty paid		4.00%
Minimum royalty payment		$ 57,500
Line of Credit [Member] | DECD [Member]
Commitments And Contingencies [Line Items]
DECD maximum borrowing capacity				$ 4,000,000
Fixed rate per annum				2.00%
Amount eligible for forgiveness				$ 2,000,000
Job creation, number of employees | employee		40
Job creation, term		2 years
Debt, maturity term		10 years
Debt penalty percentage		5.00%
DECD initial disbursement	$ 2,000,000
DECD remaining borrowing capacity				$ 2,000,000
Balance of loan		$ 1,481,000	$ 1,666,000

Commitments, Contingencies An_4

Commitments, Contingencies And Debt (Summary Of Commitments, Contigencies And Debt) (Details) $ in Thousands	Dec. 31, 2018USD ($)
Commitments, Contingencies And Debt [Abstract]
Operating leases, future minimum payments, 2019	$ 278
Operating leases, future minimum payments, 2020	140
Operating leases, future minimum payments, 2021	56
Operating leases, future minimum payments, 2022
Operating leases, future minimum payments, 2023
Operating leases, future minimum payments, Thereafter
Operating leases, future minimum payments due	474
Capital leases, future minimum payments, 2019
Capital leases, future minimum payments, 2020
Capital leases, future minimum payments, 2021
Capital leases, future minimum payments, 2022
Capital leases, future minimum payments, 2023
Capital leases, future minimum payments, Thereafter
Capital leases, future minimum payments due
Debt obligation, future minimum payments, 2019	221
Debt obligation, future minimum payments, 2020	221
Debt obligation, future minimum payments, 2021	221
Debt obligation, future minimum payments, 2022	221
Debt obligation, future minimum payments, 2023	221
Debt obligation, future minimum payments, Thereafter	516
Debt obligations future minimum payments due	1,621
Contractual obligations future minimum payments, 2019	499
Contractual obligations future minimum payments, 2020	361
Contractual obligations future minimum payments, 2021	277
Contractual obligations future minimum payments, 2022	221
Contractual obligations future minimum payments, 2023	221
Contractual obligations future minimum payments, Thereafter	516
Contractual obligations future minimum payments due	$ 2,095

Common Stock (Narrative) (Detai

Common Stock (Narrative) (Details) $ / shares in Units, $ in Thousands	Jun. 21, 2018shares	Apr. 17, 2018USD ($)	Apr. 13, 2018agreement$ / sharesshares	Feb. 17, 2017USD ($)$ / sharesshares	May 31, 2013USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares
Common Stock Equity [Line Items]
Common stock, shares issued | shares						75,501,394	60,036,017
Preferred stock, shares issued | shares						0	0
Common stock, par value | $ / shares						$ 0.001	$ 0.001
Preferred stock, par value | $ / shares						$ 0.001	$ 0.001
Proceeds from public offering | $		$ 13,500
Net proceeds after deducting offering costs from common stock issued | $						$ 8,990
Warrants outstanding to purchase shares | shares						2,810,338	2,810,338
Common stock value | $						$ 75	$ 60
Series B Convertible Preferred Stock [Member]
Common Stock Equity [Line Items]
Preferred stock, shares issued | shares			50,000
Preferred stock, par value | $ / shares			$ 0.001
Underwriting agreement, per share | $ / shares			$ 100
Percent of net proceeds of underwriting costs and other offering costs		7.00%
Proceeds from public offering | $		$ 4,496
Shares converted | shares	50,000
Common Stock [Member]
Common Stock Equity [Line Items]
Number of underwriting agreements | agreement			2
Common stock, shares issued | shares			10,000,000
Common stock, par value | $ / shares			$ 0.001
Underwriting agreement, per share | $ / shares			$ 1
Percent of net proceeds of underwriting costs and other offering costs		7.00%
Proceeds from public offering | $		$ 8,992
Over-Allotment Option [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Underwriting agreement | shares			1,500,000
Private Placement [Member]
Common Stock Equity [Line Items]
Common stock, shares issued | shares				3,747,125
Sale of stock, price per share | $ / shares				$ 1.40
Issued a warrant to purchase common stock with a cost | $ / shares				$ 0.125
Net proceeds after deducting offering costs from common stock issued | $				$ 5,127
Warrants outstanding to purchase shares | shares				2,810,338
Exercise price of warrants | $ / shares				$ 1.80
Fair value of warrants issued | $				$ 804
Common stock value | $				$ 4,323
Maximum acquisition amount under shareholder agreement without consent of at least one of the primary investors | $					$ 2,000
Minimum share and warrant ownership percentage that terminate forgoing rights for each stockholder					50.00%

Common Stock (Schedule Of Warra

Common Stock (Schedule Of Warrants Outstanding) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Number of Shares Outstanding under Warrant	2,810,338	2,810,338
February 17, 2017 - February 17, 2022 [Member]
Class of Warrant or Right [Line Items]
Issuance Date	Feb. 17, 2017
Expiration Date	Feb. 17, 2022
Exercise Price per Share	$ 1.80
Number of Shares Outstanding under Warrant	2,810,338	2,810,338

Loss Per Share (Reconciliation

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Loss (Numerator)
Net loss	$ (11,371)	$ (10,497)
Deemed dividend on warrant repricing		(942)
Net loss attributable to common stockholders	(11,371)	(11,439)
Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards
Net loss available to common shareholder - diluted	$ (11,371)	$ (11,439)
Shares (Denominator)
Net loss available to common shareholders - basic	70,085,842	56,943,596
Net loss available to common shareholder - diluted	70,085,842	56,943,596
Per Share Amount
Net loss available to common shareholders - basic	$ (0.16)	$ (0.20)
Net loss available to common shareholder - diluted	$ (0.16)	$ (0.20)

Loss Per Share (Potential Share

Loss Per Share (Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation) (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	7,434,010	7,031,610
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,612,005	4,219,568
Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,810,338	2,810,338
Unvested Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	11,667	1,704

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2015	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, exercised			32,500
Additional shares authorized			4,000,000
Total unrecognized compensation cost related to nonvested stock option awards			$ 1,540,000
Weighted average period over which unrecognized cost expected to be recognized			2 years 7 months 24 days
401(k) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
401(k) Plan, percentage for employee maximum contribution amount			90.00%
401(k) employer contributions			$ 0	$ 0
2000 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vesting period			4 years
Stock options, expiration period			10 years
Stock options, exercised			0	0
Additional shares authorized			0
2000 Stock Plan [Member] | Statutory Stock Options | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant price, percentage of fair market value of common stock			100.00%
2000 Stock Plan [Member] | Nonstatutory Stock Options | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant price, percentage of fair market value of common stock			85.00%
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, expiration period			10 years
Stock options, exercised			32,500	0
Maximum common stock provides for issuance under stock plan			12,122,983
Additional shares authorized	4,000,000	4,500,000
2010 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted share units			$ 442,000
2010 Stock Incentive Plan [Member] | Restricted Stock [Member] | Board Of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted share units				$ 281,000
Restricted share units granted			398,400	131,250
2010 Stock Incentive Plan [Member] | Restricted Stock [Member] | Certain Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of restricted share units			$ 32,000	$ 54,000
Restricted share units granted			40,606	32,332

Employee Benefit Plans (Activit

Employee Benefit Plans (Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan) (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	2,054,633	2,989,760
Shares added	4,000,000
Options canceled	879,063	779,505
Reduction in shares reserved	(18,000)	(3,050)
Granted	(1,304,000)	(1,548,000)
Restricted stock units granted	(432,877)	(163,582)
Shares available at end of period	5,178,819	2,054,633
2000 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period
Shares added
Options canceled	18,000	3,050
Reduction in shares reserved	(18,000)	(3,050)
Granted
Restricted stock units granted
Shares available at end of period
2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	2,054,633	2,989,760
Shares added	4,000,000
Options canceled	861,063	776,455
Reduction in shares reserved
Granted	(1,304,000)	(1,548,000)
Restricted stock units granted	(432,877)	(163,582)
Shares available at end of period	5,178,819	2,054,633

Employee Benefit Plans (Stock O

Employee Benefit Plans (Stock Option Activity Under 2000 Plan and 2010 Plan) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Shares
Options outstanding	4,219,568	3,451,073
Granted	1,304,000	1,548,000
Exercised	(32,500)
Canceled	(879,063)	(779,505)
Options outstanding	4,612,005	4,219,568	3,451,073
Shares exercisable	2,391,760
Shares expected to vest	1,820,601
Weighted Average Exercise Price
Opstions outstanding	$ 1.86	$ 1.70
Granted	0.98	2.05
Exercised	0.89
Canceled	1.58	1.51
Opstions outstanding	1.67	$ 1.86	$ 1.70
Shares exercisable	1.94
Shares expected to vest	$ 1.39
Aggregate Intrinsic Value
Options outstanding		$ 1,033	$ 41
Weighted Average Remaining Contractual Term
Options outstanding	7 years 2 months 1 day	8 years 7 days	8 years 5 months 16 days
Shares exercisable	5 years 8 months 19 days
Shares expected to vest	8 years 8 months 27 days

Employee Benefit Plans (Range o

Employee Benefit Plans (Range of Exercise Prices for Options Outstanding and Exercisable) (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$ 0.01
Exercise Price Upper Range	$ 11.55
Options Outstanding | shares	4,612,005
Weighted Average Exercise Price	$ 1.67
Weighted Average Remaining life	7 years 2 months 1 day
Options Exercisable | shares	2,391,760
Weighted Average Exercise Price	$ 1.94
$0.01 - $1.30 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	0.01
Exercise Price Upper Range	$ 1.30
Options Outstanding | shares	1,386,687
Weighted Average Exercise Price	$ 0.97
Weighted Average Remaining life	8 years 9 months 11 days
Options Exercisable | shares	210,687
Weighted Average Exercise Price	$ 1.01
$1.31 - $1.64 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	1.31
Exercise Price Upper Range	$ 1.64
Options Outstanding | shares	1,249,668
Weighted Average Exercise Price	$ 1.49
Weighted Average Remaining life	6 years 9 months 29 days
Options Exercisable | shares	846,042
Weighted Average Exercise Price	$ 1.49
$1.65 - $2.08 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	1.65
Exercise Price Upper Range	$ 2.08
Options Outstanding | shares	852,500
Weighted Average Exercise Price	$ 1.99
Weighted Average Remaining life	4 years 3 months 22 days
Options Exercisable | shares	714,381
Weighted Average Exercise Price	$ 1.99
$2.09 - $11.55 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	2.09
Exercise Price Upper Range	$ 11.55
Options Outstanding | shares	1,123,150
Weighted Average Exercise Price	$ 3.29
Weighted Average Remaining life	5 years 6 months 29 days
Options Exercisable | shares	620,650
Weighted Average Exercise Price	$ 2.79

Employee Benefit Plans (Fair Va

Employee Benefit Plans (Fair Value of Options Vested) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Benefit Plans [Abstract]
Total Intrinsic Value of Options Exercised	$ 9
Total Fair Value of Vested Options	$ 2,319	$ 2,272

Employee Benefit Plans (Assumpt

Employee Benefit Plans (Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Benefit Plans [Abstract]
Dividend yield
Volatility	69.00%	69.00%
Risk-free interest rate	2.69%	1.77%
Expected lives (years)	4 years	4 years
Weighted average grant date fair value	$ 0.51	$ 1.11

Employee Benefit Plans (Allocat

Employee Benefit Plans (Allocation Of Employee Stock-Based Compensation Expense By Functional Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 124	$ 136
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	6	9
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	102	160
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	869	1,134
Employee Stock-based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,191	1,152
Employee Stock-based Compensation [Member] | Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	91	82
Employee Stock-based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	6	6
Employee Stock-based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	112	150
Employee Stock-based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 982	$ 914

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Income tax benefit (expense)	$ 0	$ 0
Additional deferred tax assets	34,000	81,000
Valuation allowance	25,430,000	$ 23,320,000
Increase in valuation allowance	$ 2,000,000
Estimated annual effective rate	21.00%	34.00%
Gross unrecognized tax benefits	$ 10,967,000	$ 10,828,000	$ 10,747,000
Total Unrecognized income tax benefit, affecting effective tax rate if recognized	10,967,000
Accrued interest and penalties	0	0
Research And Development Carryforward [Member]
Income Taxes [Line Items]
Gross unrecognized tax benefits	10,967,000
Federal Tax [Member]
Income Taxes [Line Items]
Additional deferred tax assets	16,000	46,000
Gross unrecognized tax benefits	5,637,000	5,476,000	5,430,000
Federal Tax [Member] | Research And Development Carryforward [Member]
Income Taxes [Line Items]
Additional deferred tax assets	16,000
Gross unrecognized tax benefits		5,621,000
State Tax [Member]
Income Taxes [Line Items]
Additional deferred tax assets	18,000	35,000
Gross unrecognized tax benefits	5,330,000	5,352,000	$ 5,317,000
State Tax [Member] | Research And Development Carryforward [Member]
Income Taxes [Line Items]
Additional deferred tax assets	$ 18,000
Gross unrecognized tax benefits		$ 5,312,000

Income Taxes (Components Of Def

Income Taxes (Components Of Deferred Tax Assets (Liabilities)) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating losses	$ 20,614	$ 17,768
Amortization - R&D intangibles	2,410	3,091
Other	2,406	2,461
Total deferred tax assets	25,430	23,320
Valuation allowance	(25,430)	(23,320)
Deferred tax assets
Deferred tax liabilities:
Other
Deferred tax liabilities
Net deferred tax asset

Income Taxes (Reconciliation Of

Income Taxes (Reconciliation Of Statutory Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Abstract]
Tax at federal statutory rate	21.00%	34.00%
State tax, net of federal benefit	1.00%	1.00%
Valuation allowance	(19.00%)	74.00%
Permanent items		(2.00%)
Change in Federal Tax Rate (2017 Tax Reform)	2.00%	(111.00%)
Other	(5.00%)	4.00%
Effective Income Tax Rate Reconciliation, Percent, Total

Income Taxes (Reconciliation _2

Income Taxes (Reconciliation Of Change In Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
Beginning Balance	$ 10,828	$ 10,747
Return to provision true up	105
Increase in tax position	34	81
Decrease due to expirations
Ending Balance	10,967	10,828
Federal Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,476	5,430
Return to provision true up	145
Increase in tax position	16	46
Decrease due to expirations
Ending Balance	5,637	5,476
State Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,352	5,317
Return to provision true up	(40)
Increase in tax position	18	35
Decrease due to expirations
Ending Balance	$ 5,330	$ 5,352

Related Party Transactions (Det

Related Party Transactions (Details) - Former Senior Vice President, Finance And Chief Accounting Officer [Member]	12 Months Ended
	Dec. 31, 2018USD ($)
Related Party Transaction [Line Items]
Term of consulting agreement	5 months
Payment per hour	$ 150
Payments to related party	$ 53,925